Oruka Therapeutics, Inc. (NASDAQ: ORKA) is a Healthcare company (Biotechnology) with a market capitalization of $6.5B. The Maz Rating grades it against the other companies in its sector.
Oruka Therapeutics, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $96.32, Oruka Therapeutics, Inc. trades at 5.8x book value. It runs a gross margin of 0.0%, an operating margin of 0.0% and a net margin of 0.0%. It shows return on equity of -18.7%, return on invested capital of -15.3% and a free cash flow yield of -1.9%. On the balance sheet: a debt-to-equity ratio of 0.00 and a current ratio of 29.62. Over the past 52 weeks the share price ranged from $25.23 to $115.52, with a beta of -0.39.
Oruka Therapeutics, Inc. does not currently pay a dividend.
9 Wall Street analyst ratings cover the stock: 9 Buy, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Oruka Therapeutics, Inc. (ORKA) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 18.3% / 30% · Interest income / Revenue 1216600000.0% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 0.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 13.9% / 33% · Receivables / Mkt Cap (36m) 0.00% / 49% · Interest income / Revenue 1216600000.0% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 0.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 13.9% / 33.33% · Receivables / Mkt Cap (24m) 0.00% / 33.33% · Interest income / Revenue 1216600000.0% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 0.06% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 74.9% / 33.33% · Receivables / Avg Assets (4Q) 0.00% / 33.33% · Interest income / Revenue 1216600000.0% / 5% | Fail |
| FTSE | Debt / Total Assets 0.00% / 33.33% · (Cash+ST Inv) / Total Assets 74.8% / 33.33% · (Cash+Recv) / Total Assets 74.8% / 33.33% · Interest income / Revenue 1216600000.0% / 5% | Fail |
No. As of September 2026, Oruka Therapeutics, Inc. (ORKA) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Oruka Therapeutics, Inc. is over the AAOIFI limit on Interest income / Revenue.
About 1216600000.0% of each dividend: Oruka Therapeutics, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.